PrEP support via telehealth for people who inject drugs
Part of Infections clinical trials.
This trial tests whether telehealth support can help people who inject drugs start and stay on PrEP (HIV prevention medicine). You will join several sessions and follow-up visits to see if this approach works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have injected drugs at least once in the past month.
- In the last 6 months, you have had a reason to take PrEP (for example, shared needles or sex without condoms with someone at risk of HIV).
- You are already a client of the county health department’s syringe service program (SSP).
- You are willing to take part in multiple study sessions and follow-up appointments.
- You do not have HIV, and you are not already taking PrEP.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different ways to help people who inject drugs stay on PrEP, a daily pill that prevents HIV. It's for people who are HIV-negative and have recently injected drugs.
This study looks at whether getting support from friends and peers who also use drugs can help people start HIV prevention (PrEP) and treatment for substance use. The goal is to make it easier for people who inject drugs to get the care they need.
This study helps pharmacies that do not yet offer PrEP (the daily medicine that prevents HIV) learn how to start. It provides training and support on the basics of PrEP and how to make it financially sustainable.
This study tests whether pharmacies can offer HIV prevention medications (PrEP/PEP) with remote nurse support. It aims to make HIV prevention easier to access in the community.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
This study looks at how well a daily HIV prevention pill (F/TAF) works for people who use drugs. It also includes interviews with healthcare providers and peer navigators to understand how to better support patients.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.